Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 adaptive dose-ranging study of eltrekibart alone or with mirikizumab in adult patients with moderately to severely active ulcerative colitis
2023-507853-13-00Phase 2Authorised
- Sponsor
- Eli Lilly and Company
- Start
- Feb 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, IgG Antibodies → Naked Antibodies → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 23
01
Overview
Phase 2, randomised trial of eltrekibart and mirikizumab in autoimmune colitis (4 arms), sponsored by Eli Lilly and Company. Primary endpoint: Clinical remission at Week 12. Planned start Feb 2025; status: authorised.
02
Drugs
eltrekibartmirikizumab
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on 2023-507853-13-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-507853-13-00.